Abstract
Abstract
The aim of the present research work is to develop bilayer tablet dosage form containing combination of immediate and sustained release layer prepared using Glibenclamide and Metformin Hydrochloride respectively for the treatment of Type-11 diabetes mellitus. Immediate release of glibenclamide granules was prepared with different superdisintegrant. Metformin hydrochloride sustained release granules were prepared by non-aqueous wet granulation technique. Both pre-compression and post compression parameters were analyzed for all the tablets. Bilayer tablets was formulated using croscarmellose sodium for immediate release of Glibenclamide showed 99.94% of release in 30 minutes and using hydrophilic HPMC K100 and hydrophobic Ethyl cellulose in the ratio of 1:1 released 99.90% of Metformin hydrochloride for the period of 13 hours. From this research work it is evident that the formulated bilayer tablet has ability to release the Glibenclamide immediately and Metformin hydrochloride for longer period of time, which can be used for treatment of type11 diabetes mellitus compared to Marketed formulation.
References
Ritu B, Dixit, Rajat R,Gupta, Harsha V, Patel and Pradeep S, Patel Formulation and characterization of sustained release matrix Metformin hydrochloride. International Journal of pharma Recent Research, 1, (2009),P 49-53.
Giovanna corti, Marzia cirri, Francesca Maestrelli, Natascia Mennini and Paola Mura, Sustained release matrix tablet of Metformin hydrochloride in combination with triacetyl-β-cyclodextrin, Eur.J.Pharm.Biopharm.68, (2008) p303-309.
Lian Dong HU, Yang LIU, Xing Tang and Quian Zhang, Preparation and invitro/ invivo evaluation of sustained release Metformin hydrochloride pellets. Eur.J.Pharm.Biopharm.64,(2006),p185-192.
Shailendra kumar singh, Dina Nath Mishra, Rishab Jassal and Pankaj Soni, Fast disintegrating combination tablets of Omeprazole and Domperidone, Asian Journal of pharmaceutical and clinical research, 2, (2009) p74-82.
Harrower, A. (1994). Comparison of efficacy, secondary failure rate and complication of sulfonylureas. J. Diabetes Complications 8:201–203.
Mailhot, J. (1993). Efficacy and safety of gliclazide in the treatment of non-insulin dependent diabetes mellitus: a Canadian multicenter study. Clin. Ther. 15:1060–1068.
Andrew Harrower (2000), Gliclazide Modified Release: From Once-Daily Administration to 24-Hour Blood Glucose Control, Metabolism, 149:7-11.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array